Mintezol en es it fr

Mintezol Brand names, Mintezol Analogs

Mintezol Brand Names Mixture

  • No information avaliable

Mintezol Chemical_Formula


Mintezol RX_link

Mintezol fda sheet

Mintezol msds (material safety sheet)

Mintezol Synthesis Reference

No information avaliable

Mintezol Molecular Weight

192.258 g/mol

Mintezol Melting Point

246-266 oC

Mintezol H2O Solubility

1.07E+004 mg/L

Mintezol State


Mintezol LogP


Mintezol Dosage Forms

400 mg and 600 mg tablets for oral administration

Mintezol Indication

For the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgment of the physician, are life-threatening.

Mintezol Pharmacology

Tocainide is a primary amine analog of lidocaine with antiarrhythmic properties useful in the treatment of ventricular arrhythmias. Tocainide, like lidocaine, produces dose dependent decreases in sodium and potassium conductance, thereby decreasing the excitability of myocardial cells. In experimental animal models, the dose-related depression of sodium current is more pronounced in ischemic tissue than in normal tissue. Tocainide is a Class I antiarrhythmic compound with electrophysiologic properties in man similar to those of lidocaine, but dissimilar from quinidine, procainamide, and disopyramide.

Mintezol Absorption

Following oral administration, the bioavailability approaches 100 percent, and is unaffected by food.

Mintezol side effects and Toxicity

The oral LD50 of tocainide was calculated to be about 800 mg/kg in mice, 1000 mg/kg in rats, and 230 mg/kg in guinea pigs; deaths were usually preceded by convulsions.

Mintezol Patient Information

Mintezol Organisms Affected

Humans and other mammals